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Abstract
Myeloid blood cells are largely resistant to infection with human immunodeficiency virus type 1 (HIV-1). Recently, it was
reported that Vpx from HIV-2/SIVsm facilitates infection of these cells by counteracting the host restriction factor SAMHD1.
Here, we independently confirmed that Vpx interacts with SAMHD1 and targets it for ubiquitin-mediated degradation. We
found that Vpx-mediated SAMHD1 degradation rendered primary monocytes highly susceptible to HIV-1 infection; Vpx with
a T17A mutation, defective for SAMHD1 binding and degradation, did not show this activity. Several single nucleotide
polymorphisms in the SAMHD1 gene have been associated with Aicardi-Goutie `res syndrome (AGS), a very rare and severe
autoimmune disease. Primary peripheral blood mononuclear cells (PBMC) from AGS patients homozygous for a nonsense
mutation in SAMHD1 (R164X) lacked endogenous SAMHD1 expression and support HIV-1 replication in the absence of
exogenous activation. Our results indicate that within PBMC from AGS patients, CD14+ cells were the subpopulation
susceptible to HIV-1 infection, whereas cells from healthy donors did not support infection. The monocytic lineage of the
infected SAMHD1 -/- cells, in conjunction with mostly undetectable levels of cytokines, chemokines and type I interferon
measured prior to infection, indicate that aberrant cellular activation is not the cause for the observed phenotype. Taken
together, we propose that SAMHD1 protects primary CD14+ monocytes from HIV-1 infection confirming SAMHD1 as a
potent lentiviral restriction factor.
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Introduction
Cells of the myeloid lineage are more refractory to HIV-1
infection than T-cells [1–4]. HIV-2 and SIV from sooty
mangabeys (SIVsm) but not HIV-1 encode the accessory protein
Vpx [5] that provides a replication advantage in human myeloid
cells [6,7]. Moreover, Vpx deficient HIV-2/SIVsm viruses are
attenuated in vivo [8]. The delivery of Vpx in trans through virus-
like particles (VLP) also enables HIV-1 to infect otherwise resistant
primary human cells such as monocytes [3,9,10] or dendritic cells
[6,11]. Furthermore, Vpx promotes HIV infection of macrophag-
es and PMA-differentiated THP-1 cells [12]. Vpx is packaged into
budding virions via interaction with the p6 domain of Gag [13]
and is active during the early steps of infection in the target cell
[5].
Lentiviral accessory proteins counteract known restriction
factors such as APOBEC3G or tetherin by mediating their
ubiquitin/proteasome-dependent degradation [14,15]. Similarly,
it has been proposed that Vpx allows lentiviral escape by targeting
a myeloid cell-specific restriction factor [3,16,17] for proteasomal
degradation [18]. Two recent publications identified Sterile Alpha
Motif (SAM) Domain and HD domain-containing protein 1
(SAMHD1) as the Vpx-sensitive restriction factor that inhibits
HIV-1 infection of macrophages and dendritic cells [19,20].
The SAMHD1 gene is mutated in a subset of patients suffering
from Aicardi-Goutie `res syndrome (AGS), an early-onset disease
that resembles a congenital viral infection [21]. This syndrome is
characterized by familial encephalopathy with predominantly
neurologic symptoms [22] and increased production of interferon
alpha (IFNa) in the brain [23]. Single nucleotide polymorphisms
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associated with autoimmunity disorders such as AGS and
systematic lupus erythematosus [22]. It has been assumed that
the absence of the endonuclease RNASEH2 or the exonuclease
TREX1 leads to accumulation of endogenous nucleic acids
inducing type I IFN-mediated immune response [24,25]. In
contrast, the role of SAMHD1 in nucleic acid metabolism is not
well defined. Moreover, cerebral vasculopathy and strokes
accompanied by an altered cytokine secretion pattern have been
reported in patients with SNPs in the SAMHD1 gene [26–29].
In this report, in addition to confirming independently the
findings by Laguette et al. and Hrecka et al. [19,20], we provide
further evidence for the role of SAMHD1 as interferon-induced
factor restricting HIV-1 replication in monocytes, the progenitors
of macrophages and dendritic cells. We demonstrate that
SAMHD1 is targeted for ubiquitin-mediated degradation in a
Vpx-dependent fashion in primary CD14 positive monocytes. We
also found that unstimulated primary peripheral blood mononu-
clear cells (PBMC) from two AGS patients lacking endogenous
SAMHD1 can support viral replication whereas cells from healthy
donors encoding wild-type (WT) SAMHD1 were resistant to HIV-
1 infection. Microscopy imaging of infected AGS and healthy
donor cells suggest that CD14+ cells of monocytic morphology are
the cells targeted by HIV-1 in the absence of SAMHD1.
Results
SAMHD1 Interacts with Vpx and Is Depleted in a Process
that Is Reversible by Addition of MG132
To uncover novel Vpx (VpxSIVsmPBi)-interaction partners in
293T cells, tandem affinity purification was performed and
isolated proteins were identified by mass spectrometry analysis
(Figure 1A and S1). In addition to confirmed Vpx interacting
proteins such as VprBP [30] and DDB1 [17] we isolated a 72 kDa
protein, which was determined to be SAM domain and HD
domain containing protein 1 (SAMHD1). In order to confirm the
protein interaction, endogenous SAMHD1 was co-immunopre-
cipitated with HA-VpxSIVsmPBi, whereas interaction with an
inactive Vpx mutant, T17A (Figure 1B) [6,12], was significantly
reduced (Figure 1C). The functional relevance of the SAMHD1-
Vpx interaction on a single cell level was further determined by
confocal fluorescence microscopy. We observed that expression of
wild-type (WT) Vpx leads to a drastic reduction of endogenous
nuclear SAMHD1 levels (Figure 1D). Of note, Vpx T17A
displayed a cellular distribution similar to that of its WT
counterpart (both in nuclei and cytoplasm), but was unable to
deplete SAMHD1 (Figure 1D).
Next we probed for the importance of ubiquitin-conjugated
protein degradation in the Vpx-mediated reduction of SAMHD1.
We observed that the peptide aldehyde proteasome inhibitor
MG132 blocked Vpx-mediated depletion of SAMHD1 in THP-1
cells (Figure 1E). The Vpx mutant T17A failed to induce
degradation of SAMHD1 (Figure 1E).
Our findings are in agreement with the recent reports of
Laguette et al. [20] and Hrecka et al. [19] that identified SAMHD1
as a VpxSIVmac251 and VpxHIV2 interacting protein. Taken
together, these results demonstrate that Vpx targets SAMHD1
for ubiquitin-mediated degradation.
SAMHD1 Restricts HIV-1 Infection in Monocytic Cells
We next tested the hypothesis that the efficiency of HIV-1
infection in monocytic cells correlates directly with Vpx-mediated
degradation of SAMHD1. We transduced PMA-differentiated
THP-1 cells with VLPs carrying WT Vpx, the Vpx T17A mutant
or empty VLPs and subsequently infected them with a single-cycle
VSV-G pseudotyped HIV-1 luciferase reporter virus (HIV-1-luc).
We found that HIV-1 infection was 12.6-fold higher in the
presence of WT Vpx, compared to mutant Vpx or empty particles
(Figure 2A), and this phenotype correlated with the degradation of
SAMHD1 in these cells (Figure 2A, lower panel).
To test the efficiency of HIV-1 restriction by endogenous
SAMHD1, we infected differentiated THP-1 cells stably express-
ing shRNA targeting SAMHD1 or a non-targeting control shRNA
with HIV-1-luc (Figure 2B, lower panel). Infection with single-
round HIV-1-luc was up to 4.5-fold higher in SAMHD1 shRNA
expressing cells than in control cells (Figure 2B).
Next, we assessed whether Vpx-mediated HIV-1 infection also
affects SAMHD1 levels in primary monocytes. Therefore,
monocytes were infected with a lentiviral HIV vector expressing
GFP (HIV-1-EGFP) in the presence or absence of Vpx. In line
with the experiments in THP-1 cells (Figure 2A), delivery of Vpx
relieved restriction of HIV-1-EGFP whereas Vpx T17A did not
render these cells susceptible for HIV-1 (Figure 2C). Also in
monocytes, the permissiveness to HIV-1 correlated with the Vpx-
induced reduction of SAMHD1 in a ubiquitin-dependent pathway
(Figure 2D). We conclude that monocytes express SAMHD1 as an
interferon-inducible factor (Figure 2E) that is degraded upon Vpx-
supported HIV-1 infection confirming the results in dendritic cells
[20] and macrophages [19].
Cells from Aicardi-Goutie `res Syndrome Patients Lacking
SAMHD1 Support Spreading Infection of HIV-1
To determine whether cells with a nonsense mutation in
SAMHD1 obtained from AGS patients might be more susceptible
to viral infection, we tested HIV-1 infectivity in PBMC from two
related AGS patients described previously [28]. The cause of AGS
in these patients was assigned to an homozygous mutation in
SAMHD1, which introduces a premature stop codon at position
164. This results in a truncated protein lacking the HD domain
(Figure 3A). The composition of PBMC subpopulations from AGS
patients showed no obvious SAMHD1-dependent deviation from
PBMC of healthy donors (Figure 3B). PBMC from patients
homozygous for SAMHD1 R164X as well as WT SAMHD1 were
stimulated with interleukin 2 (IL-2) and PHA followed by
subsequent infection with the replication-competent CCR5-tropic
HIV-1 SF162. Interestingly, HIV-1 spread in both healthy and
AGS primary cells to a comparable degree (Figure 3C, left panel).
Author Summary
Lentiviral accessory proteins play important roles in
antagonizing host proteins aimed at suppressing HIV-1
replication at a cellular level. The SIV/HIV-2 protein Vpx
counteracts SAMHD1, a previously unknown antiviral
factor within myeloid blood cells, rendering these cells
permissive to primate immunodeficiency viruses. We
confirm in this study that Vpx interacts with SAMHD1
leading to ubiquitin-mediated degradation of SAMHD1,
and renders CD14 positive monocytes susceptible to HIV-1
infection. We provide new insights into the ability of
SAMHD1 to protect monocytic cells from HIV-1 infection
by using primary cells from patients with Aicardi-Goutie `res
syndrome (AGS) lacking endogenous SAMHD1 expression.
We show that peripheral monocytic cells of AGS patients
are highly permissive to HIV-1. Thus, our study demon-
strates that SAMHD1 is critical for restriction of HIV-1
infection in monocytes adding SAMHD1 as a novel innate
defense factor.
SAMHD1 Protects Monocytes from HIV-1 Infection
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full-length, but also truncated SAMHD1 in AGS patients (Figure
S2), suggesting that the R164X mutation reduces protein stability
or induces nonsense-mediated decay of the transcript. To exclude
the impact of mitogen-stimulated T-lymphocytes on HIV-1
replication that might conceal the restrictive role of SAMHD1,
we repeated this experiment in the absence of IL-2/PHA
stimulation. In non-stimulated cells, HIV-1 spread far more
rapidly in SAMHD1 R164X PBMC than in PBMC from healthy
individuals (Figure 3C, right panel). These findings suggest that, in
the absence of exogenous stimulation, SAMHD1 deficiency
renders a subpopulation of cells within PBMC susceptible to
HIV-1 replication. However, upon mitogenic T-cell stimulation,
the absence of SAMHD1 has no further advantage for HIV-1
replication likely because the bulk of the viral replication occurs in
activated T-lymphocytes masking the putative replication in less
abundant cell populations.
To confirm the SAMHD1-dependent effect of HIV-1 replica-
tion in non-stimulated PBMC, we infected AGS and healthy
donor PBMC with R7/3-YU2-EGFP, a CCR5-tropic HIV virus
that encodes GFP in place of Nef [31,32]. However, due to the
limited availability of clinical specimen from AGS patients, we
could perform these experiments only with PBMC from one of the
two AGS patients (Donor 2). Despite low viral input (MOI: 0.01)
we observed also in this experimental setup, a sustained replication
in non-stimulated AGS PBMC starting as early as day 3 after
infection (Figure 3D). No p24 production was observed in PBMC
from the healthy Donor 4 within seven days of infection
(Figure 3D).
These results indicate that the absence of SAMHD1 due to the
R164X mutation supports a spreading replication of HIV-1 in
non-stimulated primary cells normally refractory to HIV-1.
HIV-1 Predominantly Infects CD14+ Monocytes in
SAMHD1-deficient PBMC
Next, we sought to further define the primary cell population
infected with R7/3-YU2-EGFP. The infections of PBMC from
Donor 2 (SAMHD1 -/-) and healthy Donor 4 (SAMHD1 +/+)
were inspected by live cell fluorescence microscopy at day 7. In
agreement with the replication data (Figure 3D), 10% of
SAMHD1 -/- cells (Donor 2) were GFP/HIV-1 positive at day
7 post infection whereas PBMC from Donor 4 did not yield green
fluorescent cells at any time point (Figure 4A).
Because most of the HIV-1 positive cells were much larger than
T-lymphocytes and exhibited a morphology similar to myeloid
cells, we stained the cells for the myeloid cell marker CD14 at day
7 post infection in order to determine the susceptibility of this
lineage to HIV-1. Counting the cells represented in independent
microscopic images (Donor 2: 16 images and Donor 4: 12 images)
revealed that within the SAMHD1-deficient specimen 80% of
GFP/HIV-1+ cells were positive for CD14 (see Figure 4B and 4C
for examples and Figure 4D for quantification). Interestingly, at
day 7 of the experiment, the overall percentage of CD14+ cells was
higher in the AGS sample (Donor 2: 26% HIV-1 infected, 34%
mock infected versus Donor 4: 7% and 8% respectively; 12
independent images; Figure S3), although the frequency of CD14+
cells post isolation were comparable between Donor 2 and Donor
4 (Figure 3B). In summary, these live cell microscopy experiments
support the notion that within non-stimulated PBMC lacking
functional SAMHD1, CD14+ monocytic cells are the subpopu-
lation that are highly susceptible to HIV-1 infection.
Activation of SAMHD1 -/- and SAMHD1 +/+ Cells before
and after HIV-1 Infection
To determine the interferon and cytokine/chemokine responses
during HIV-1 replication, we analyzed the culture supernatants of
R7/3-YU2-EGFP or non-infected cells from Donor 2 (SAMHD1
-/-) and Donor 4 (SAMHD1 +/+) using multiplex-ELISA. Prior to
infection, cytokine and chemokine levels were low or undetectable
in Donor 2, suggesting that the cells were not activated due to the
absence of SAMHD1 (Figure 5, purple line).
Only in AGS PBMC, early pro-inflammatory cytokines such as
IL-6, IP-10, TNFa and MIP-1b were induced during the seven
day course of HIV-1 replication (Figure 5, green and orange lines).
IL-6 and IP-10 were stimulated more than 20-fold at day 3 and
more than 15-fold at day 4, respectively, compared to the low level
induction in healthy donor 4, suggesting an early inflammatory
reaction upon HIV-1 in SAMHD1-deficient PBMC (Figure 5,
orange and blue lines). These cytokines are also indicative of a
cytokine response primarily produced by cells of monocytic origin
[33,34]. Notably, IFN-a, IFN-c, the CCR5-ligand RANTES and
the cytokine IL-1b were neither induced upon HIV-1 replication
in SAMHD1-deficient cells nor upon HIV-1 incubation with
healthy donor PBMC (Figure 5). We also could not detect
evidence for secretion of bioactive type I interferon using a
sensitive interferon bioassay (Figure S4).
Discussion
In this study, we determine the role of SAMHD1 as a HIV-1
restriction factor in human monocytes confirming and extending
the findings observed in other myeloid cells [19,20]. Previous
reports have determined that residue 17 in Vpx is crucial for the
infection of macrophages and dendritic cells [6,12]. Our results,
using a Vpx T17A mutant, explain this observation by revealing
that the Vpx-SAMHD1 interaction most probably occurs via the
region encompassing Vpx residue 17. Moreover, we confirm the
effect of the proteasome inhibitor MG132 on the reversibility of
Vpx-mediated degradation of SAMHD1 [19,20]. MG132 inhibi-
tion of the proteasome can also have the effect of depleting cellular
ubiquitin levels and, thus, block any ubiquitin-dependent processes
[35]. Vpx-mediated SAMHD1 depletion may, therefore, be due to
proteasomal degradation or other ubiquitin-dependent mecha-
nisms (e.g., ubiquitin dependent recruitment to the lysosome).
Figure 1. SAMHD1 is identified as Vpx binding protein leading to its degradation. A) pNTAP-SIV Vpx was transfected in 293T cells. After
lysis, isolation of SIV-Vpx and binding proteins was performed via Tandem Affinity Purification. The proteins were separated by SDS-PAGE and stained
with Coomassie Brilliant Blue. Protein bands in which the respective protein was identified are indicated. B) Schematic representation of the Vpx
protein indicating the helical structure elements (black) and the introduced T17A mutation. C) 293T cells were transfected with pcDNA3.1 (mock) or
plasmids encoding HA-Vpx or HA-Vpx T17A. After 48 hours, the cells were lysed and subjected to HA-immunoprecipitation. Isolated proteins were
separated via SDS-PAGE and analyzed with antibodies specific for HA or SAMHD1. D) HeLa cells endogenously expressing SAMHD1 were transfected
with pcDNA3.1 (mock) or HA-Vpx or HA-Vpx T17A encoding plasmids. 24 hours after transfection, the cells were fixed and stained for SAMHD1 and
HA-Vpx with fluorescent antibodies. Nuclei were stained with DAPI before performing confocal microscopy. White arrows indicate nuclei of Vpx
expressing cells, in which SAMHD1 is absent. White bar length corresponds to 10 mm. E) THP-1 cells were incubated with 2 MOIeq of empty VLPs (Ø),
Vpx-VLPs or Vpx T17A-VLPs in the presence or absence of 50 mM MG132. After 6 hours the cells were analyzed by western blot analysis with the
indicated antibodies.
doi:10.1371/journal.ppat.1002425.g001
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for 24 hours before they were transduced with empty VLPs (Ø) or VLPs carrying Vpx (VLP VPX) or Vpx T17A mutant (VLP Vpx T17A) with a MOIeq of 2.
Two hours after transduction the cells were infected with HIV-1-luc. Luciferase activity was determined 24 hours after infection. In parallel, uninfected
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as a protein-binding [36] or RNA-binding domain [37] and a HD
domain characterized by a doublet of histidine/aspartic acid
residues. The latter is presumed to bind nucleic acids [38] and to
serve as a phosphohydrolase/nuclease domain [39,40]. As with
other HIV-1 restriction factors such as Tetherin, TRIM5a and
APOBEC3G that are up-regulated by interferon [41,42], we find
that SAMHD1 is regulated by type I IFN. This is consistent with
earlier reports suggesting that the host molecule targeted by Vpx is
inducible by type I interferon, which was reported to magnify the
Vpx phenotype on HIV-1 infection in macrophages [12]. Besides
SAMHD1, the myeloid-specific protein APOBEC3A was reported
to be counteracted by Vpx [9,43], suggesting that either protein
might act as co-factor for antiviral activity.
Expression of Vpx or silencing of SAMHD1 was reported to
induce viral DNA accumulation [3,20], suggesting that the
restriction takes effect at or before reverse transcription [44].
Since SAMHD1 is located in the nucleus (see Figure 1D and
[20,25]), it either might act on components of the pre-integration
complex after nuclear entry or it is exported to the cytoplasm
during the early phases of infection.
Most interestingly, we observe a spreading replication of HIV-1
in non-stimulated PBMC from AGS patients homozygous for
SAMHD1 R164X. Although one should take into account that
cells of only one AGS patient were analyzed, our data suggest that
predominantly cells of the CD14 positive monocytic lineage
became highly susceptible targets for HIV-1 compared to HIV-1
resistant cells of healthy donors. The infected patient cells
displayed an early inflammatory cytokine secretion profile that
might be interpreted as a monocytic cell specific response to HIV-
1 infection. We conclude therefore that SAMHD1 protects
monocytic cells from HIV-1 infection. Upon T-cell stimulation
in PBMC, the enabled HIV-1 replication did not additionally
benefit from SAMHD1 deficiency, allowing the speculation that
SAMHD1 might not contribute to HIV-1 restriction in T-cells.
However, in this context other restriction-associated cellular
determinants and cell type-specific SAMHD1 expression level
have to be considered in future studies.
In conclusion, our study sheds light on how HIV-1 and the
host’s antiviral innate immune responses intersect. Understanding
cell-type specific barriers to HIV-1 infection such as mediated by
SAMHD1 will be important to develop innovative therapies and
vaccines.
Materials and Methods
Ethics Statement
Buffy-coats obtained from anonymous blood donors were
purchased from the German blood donation center. Whole blood
was obtained from AGS patients that signed an informed consent.
The research has been approved by the Ethics Committee of the
Chamber of Physicians Westfalen-Lippe and the Medical Faculty
of the Westfalian Wilhelms University Mu ¨nster (Reference No
2006-556-f-S) and performed according to the principles expressed
in the Declaration of Helsinki.
Tandem Affinity Purification and Mass Spectrometry
Codon-optimized SIV Vpx from SIVsm PBj1.9 was cloned into
pNTAP of the Interplay Mammalian TAP System (Stratagene).
293T cells were transfected and cultivated for 48 hours. One hour
before lysis, cells were incubated with 100 ng/ml PMA.
Purification was performed as described in the manufacturer’s
instructions. Proteins associated with the Calmodulin-binding
beads were subjected to SDS-PAGE, stained with Coomassie
brilliant blue, digested with trypsin and analyzed by tandem mass
spectrometry (MS/MS) at the Paul-Ehrlich-Institute.
Plasmids
Codon-optimized N-terminal HA-tagged SIV Vpx derived from
SIVsm PBj1.9 [9] and N-terminal FLAG-tagged SAMHD1 were
cloned into pcDNA3.1. The Vpx T17A mutant was generated
using the Site-Directed Mutagenesis Kit (Stratagene). Codon-
optimized SIV Vpx from SIVsm PBj1.9 was cloned into pNTAP
of the Interplay Mammalian TAP System (Stratagene).
Cell Culture and Primary Cell Isolation
HEK 293T and HeLa cells were grown in Dulbecco’s modified
Eagle’s medium, THP-1 cells were grown in RPMI medium, both
containing 1 mM L-glutamine and 10% fetal calf serum (FCS).
Anonymized buffy coats were purchased from the German blood
donation center for isolation of primary human monocytes with
the Monocyte Isolation Kit II (Miltenyi) and the isolated cells were
cultured as described previously [9]. For stimulation, monocytes
were incubated with interferon a (Sigma # I4784 & ProSpec #
Cyt204B).
PBMC were isolated using a Ficoll gradient from whole blood
obtained from healthy donors and AGS patients that signed an
informed consent. Of note, AGS patient Donor 1, but not Donor 2
was treated with immunosuppressive medication at time of blood
collection. PBMC were cultivated in RPMI, Pen/Strep, and 20%
FCS.
Viral Particle Production, THP-1 and Monocyte
Transduction
HEK 293T cells were co-transfected with the SIV PBj1.9-
derived packaging construct PBj-psi10 [10], pMD.G coding for
VSV-G and the appropriate pcDNA3.1 expression plasmid
encoding WT Vpx or Vpx T17A for generation of Vpx-containing
VLPs. For generation of empty VLPs, pcDNA3.1 was used instead
of a Vpx-expressing plasmid as described earlier [9]. For
generation of HIV-1 EGFP, the plasmid pHR-CMV-EGFP, the
HIV-1 packaging construct pCMVDR8.9 and pMD.G for
generation of HIV-1 particles were used as described before
[10]. Production of HIV-1-luc single-cycle reporter particles was
performed by transfection of HEK 293T cells with pNL4.3R
+E
-
THP-1 cells were lysed six hours after VLP transduction and subjected to western blot analysis with the indicated antibodies (lower panel). B) THP-1
cells were transduced with lentiviral particles encoding for a non-specific shRNA (shControl) or a shRNA against SAMHD1 (shSAMHD1 #1; #2) and
selected with puromycin. PMA stimulated THP-1 shControl or THP-1 shSAMHD1 (#1; #2) cells were infected with HIV-1-luc. After 24 hours, the
luciferase activity was determined. In parallel, uninfected cells were subjected to western blot analysis using the indicated antibodies (lower panel). C)
One day post-isolation, primary human monocytes were incubated with 2 MOIeq of VLPs containing no Vpx, WT Vpx or Vpx T17A and HIV-1-EGFP
(MOI 8). EGFP expression was determined by FACS five days post infection. The experiment was repeated twice with different donors and the results
of a representative experiment are shown here. D) Primary human monocytes were transduced with 2 MOIeq empty VLPs, Vpx VLPs or Vpx T17A VLPs
and cultured w/o MG132 (50 mM) for 6 hours. The cells were lysed and analysed by immunoblot for expression of SAMHD1 and GAPDH. Mock
indicates untransduced cells. E) Primary human monocytes were stimulated with 2, 20 or 200 ng/ml IFNa (ProSpec) for 24 hours or with 20 ng/ml IFN
(Sigma) for 48 hours. The cells were lysed and SAMHD1 was detected with the respective antibody in western blot analysis.
doi:10.1371/journal.ppat.1002425.g002
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gen) according to the manufacturer’s instructions. Purification of
particles and titration of HIV-1 EGFP was described earlier [10].
The amount of VLPs and HIV-1-luc was determined with the
Lenti RT Activity Kit (Cavidi). The VLPs were normalized in
comparison to PBj-derived vectors of known infectivity. The
amount of VLPs per cells was given as MOI-equivalents (MOIeq).
Transduction of THP-1 cells with VLPs was performed with a
MOI of 2. Infection of the cells was accomplished with 2.5 ng RT
HIV-1-luc two hours after VLP transduction. For single-round
infection, monocytes were exposed to HIV-1-EGFP for 4 hours
and subjected to flow-cytometry analysis five days post-transduc-
tion. For MG132 treatment, the cells were cultured with 50 mM
MG132 (Calbiochem) for 30 minutes before transduction.
PBMC Infection and FACS Analysis
Infections were done with two different CCR5 using HIV-1
viral stocks (SF162, R7/3 EGFP). For analysis of HIV-1 SF162
virus replication, PBMC were infected in triplicate with 0.05 MOI
of R5-tropic HIV-1 SF162 and cultured up to day 14. Virus in the
supernatant was quantified with the Lenti RT Activity Kit
(Cavidi). For FACS analysis of PBMC, the cells were fixed and
stained with PE-labelled anti-CD14, FITC-labelled anti-CD3, PE-
labelled anti-CCR5 (all BD) and PE-labelled anti-CD4 (DAKO)
according to the manufacturers instructions. For the infections
performed with virus stock HIV-1 R7/3 envYU2-EGFP [31,32],
2610
5 PBMC were infected in triplicate with 0.75 ng or 3.75 ng
p24 equivalent for 5 hours. Cells were washed after infection and
cultured for 7 days in a 96 well plate. Culture supernatants were
collected every day and stored at 280uC. Viral spread was
monitored by measuring p24 concentrations in the culture
supernatants using a p24 ELISA assay (XpressBio) and by
monitoring GFP expression by fluorescent microscopy.
DNA Transfection and Co-Immunoprecipitation (CoIP)
Experiments
293T cells were transiently transfected with the respective
plasmids using Lipofectamine 2000 (Invitrogen) according to the
manufacturers instructions. For transfection of HeLa cells, Fugene
6 (Roche) was used in accordance with the manufacturer’s
instructions. For CoIP transfected cells were lysed, sonicated and
incubated with anti-HA beads (Roche). After 1h incubation at 4 C,
the beads were washed with lysis buffer and associated proteins
were subjected to SDS-PAGE.
Immunoblot and Antibodies
Cells were lysed in RIPA buffer and sonicated. When using
interferon, monocytes were incubated with IFN-a (ProSpec, cat#
Cyt204B or Sigma cat#I4784) 48 hours before lysis. Protein
extracts were separated via SDS-PAGE and transferred to a
nitrocellulose membrane (GE Healthcare). For detection, anti-HA
(Roche), anti-SAMHD1 (abcam), anti-tubulin and anti-GAPDH
(all Cell Signaling Technology) were used as primary antibodies.
Secondary HRP-conjugated anti-mouse and anti-rabbit antibodies
were obtained from GE Healthcare.
Cell Staining and Microscopy
HeLa cells were seeded on a LabTek chambered coverglass
(Nunc) and transfected with expression plasmids for Vpx using
Fugene 6 (Roche). After 24 hours, cells were fixed, permeabilized
and blocked as described previously [9]. Cells were incubated with
anti-HA (Roche) and anti-SAMHD1 (abcam) primary antibodies
and stained with secondary Alexa-Fluor 594 anti-rabbit, Alexa-
Fluor 488 anti-mouse antibodies (both Invitrogen) and DAPI
(Chemicon). Images were acquired with a ZEISS LSM Meta
confocal microscope. Live cell imaging of infected and non-
infected PBMC from Donor 2 (SAMHD1 -/-) and Donor 4
(SAMHD1 +/+) was performed at the Microscopy Core Facility at
MSSM, NY. At day 7 of infection, cells were washed once
carefully with warm PBS/1% FBS and stained with anti-human
CD14-PE (Clone MEM-15, Abcam, USA) and mouse IgG1-PE
(Clone X40, BD Biosciences, USA) for 30 minutes in the 96 well-
plate in which the infections were performed. After three washes
Hoechst 33342 (10 mM final concentration) stain was added for 30
minutes. Imaging was performed on Olympus IX70 microscope
with a live cell imaging system (37uC, 5% CO2). Images were
acquired with 20x and 40x lenses.
SAMHD1 Knockdown and Luciferase Reporter
Experiments
THP-1 stable cell lines were generated by transduction with
lentiviral vectors encoding unspecific shRNA (pLKO-nontarget)o r
shRNA specific to SAMHD1 (shSAMHD1 #1 TRCN0000
343807: sequence: CCGGCCCTGAAGAAGATATTTGCTTC-
TCGAGAAGCAAATATCTTCTTCAGGGTTTTTG); shSAM
HD1 #2 TRCN0000343808: sequence CCGGGCCATCATC-
TTGGAATCCAAACTCGAGTTTGGATTCCAAGATGAT-
GGCTTTTTG) (all Sigma) and selected with puromycin. For
HIV-1 luciferase reporter assays, 2.5610
4 THP-1 cells were
stimulated with 5 ng/ml PMA (Calbiochem) overnight and
infected by spin-occulation with HIV-1-luc. Luciferase activity
was detected using BriteLite reagent (PerkinElmer) according to
the manufacturer’s instructions 24 hours post infection.
Multiplex ELISA
Quantification of IL-6, IP-10, TNF-a, MIP-1b, IFN-a, IFN-c,
RANTES and IL-1b release in supernatants of infected and non-
infected PBMC from Donor 2 (SAMHD1 -/-) and Donor 4
(SAMHD1 +/+) was performed using the MILLIPLEX Multi-
Analyte Profiling Human Cytokine/Chemokine Kit (Millipore,
MA, USA) according to the manufacturer’s instructions. Data
were analyzed using the Milliplex Analyst software.
IFN Bioassay
Functional type I interferon was detected using a bioassay
previously described [46]. Vero cells were incubated with serial
Figure 3. PBMC from AIcardi-Goutie `res syndrome patients homozygous for SAMHD1 mutation are highly susceptible for spreading
HIV-1 replication. A) Schematic representation and domain structure of SAMHD1 and SAMHD1 R164X, indicating the truncation of SAMHD1 after
insertion of a STOP codon observed in two AGS patients. B) PBMC from healthy donors (Donor 3/4 +/+) and AGS patients homozygous for SAMHD1
R164X (Donor 1/2 -/-) were isolated by Ficoll gradient, fixed and stained with PE-labeled anti-CD14, PE-labeled anti-CCR5, FITC-labeled anti-CD3 and
PE-labeled anti-CD4 for FACS analysis. The numbers indicate the relative amount of the respective subpopulation within PBMC. C) A fraction of
isolated PBMC described in (B) was stimulated with 250 ng/ml PHA & 180 U/ml IL-2 for 18 hours (left graph) or were left non-stimulated (right graph)
prior to infection in triplicate with 0.05 MOI of HIV-1 SF162. At indicated days post-infection, the supernatants were analyzed for reverse transcriptase
(RT) activity. D) A fraction of isolated Donor 2 (SAMHD1 -/-) and Donor 4 (SAMHD1 +/+) PBMC analyzed in (B) were infected in triplicate with HIV R7/3
YU2 EGFP or mock infected. At indicated days post-infection, the culture supernatants were analyzed for p24 concentration by ELISA.
doi:10.1371/journal.ppat.1002425.g003
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PLoS Pathogens | www.plospathogens.org 8 December 2011 | Volume 7 | Issue 12 | e1002425Figure 4. Monocytic cells lacking SAMHD1 are target cells for HIV-1. A) PBMC of the SAMHD1-deficient Donor 2 and the healthy Donor 4
were infected in triplicate with HIV-1 R7/3 YU2 EGFP as described in Figure 3D. After 7 days in culture, staining was performed with CD14-PE (red) and
Hoechst 33342 (DNA staining, blue). GFP expression (green) indicates HIV infected cells. Images were acquired with 20x and 40x lenses on an
Olympus microscope with live imaging system. B) Magnified selected composite image from infected cells derived from Donor 2 (SAMHD1 -/-). C)
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PLoS Pathogens | www.plospathogens.org 9 December 2011 | Volume 7 | Issue 12 | e1002425Magnified selected composite images from infected cells derived from Donor 2 (SAMHD1 -/-) and Donor 4 (SAMHD1 +/+). Arrows identify CD14+
(red), GFP/HIV+ (green) and CD14+/GFP/HIV-1 + cells (orange). D) Percentage of CD14+ and CD14- cells within HIV-1/GFP+ cells from Donor 2
(SAMHD1 -/-) determined by cell counting of 16 independent microscopy images.
doi:10.1371/journal.ppat.1002425.g004
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PLoS Pathogens | www.plospathogens.org 10 December 2011 | Volume 7 | Issue 12 | e1002425dilutions of culture supernatant of uninfected or HIV-1 infected
PBMC for 24 hours and then infected with GFP-encoding
Newcastle disease virus (NDV-GFP) (MOI of 1). GFP was
measured 18 hours post-infection. A serial dilution of recombinant
IFN-b served as positive control and standard.
Supporting Information
Figure S1 Vpx binding proteins identified by mass
spectrometry. Prominent SIV-Vpx binding proteins isolated
by tandem affinity purification and identified by mass spectrom-
etry (MS/MS) are listed. The individual SwissProt accession
numbers and ProteinLynx Global Server 2.3 (PLGS) scores for
detection in the UniProt database are given for each protein.
Peptides indicate the number of peptides that can be aligned with
the respective proteins. The coverage indicates the percentage of
protein amino acid sequence that is covered by the peptides
assigned to the respective database entry.
(TIF)
Figure S2 Absence of SAMHD1 expression in cells of
AGS patients. PBMC from healthy donors (Donor 3/4 +/+)o r
AGS patients homozygous for R164X SAMHD1 (Donor 1/2 -/-)
were isolated and infected as described in Figure 3C (left panel). At
day 14 post-infection, the cells were lysed and subjected to western
blot analysis with the indicated antibodies.
(TIF)
Figure S3 CD14+ non-infected cells of AGS patient 2 and
healthy Donor 4. A) PBMC from a healthy donor (Donor 4) or
an AGS patient with homozygous R164X SAMHD1 mutation
(Donor 2) were cultured for seven days. The cells were stained with
PE-labeled CD14-targeting antibody and analyzed by live cell
fluorescent microscopy (Olympus IX-70, 20x magnification). B)
Relative amount of CD14+ cells within cells from Donor 2
(SAMHD1 -/-) and Donor 4 (SAMHD1 +/+) determined by cell
counting of 16 and 12 independent microscopy images, respec-
tively, taken after 7 days of cultivation, as exemplarily shown in
Figure S3A.
(TIF)
Figure S4 HIV-1 infection of PBMC from AGS patient 2
and healthy Donor 4 does not induce type I interferon.
Vero cells were incubated with serial dilutions of culture
supernatant from day 7 of uninfected (mock) or HIV-1 infected
(+ HIV) PBMC of a healthy donor (Donor 4 SAMHD1 +/+)o ra n
AGS patient (Donor 2 SAMHD1 -/-) for 24 hours and were then
infected with interferon sensitive GFP-encoding Newcastle disease
virus (NDV) with a MOI of 1. GFP was measured 18 hours post-
infection by fluorometry. A serial dilution of recombinant IFN-b
served as positive control (lower panel, IFN-b), mock addition as
negative control (lower panel, mock).
(TIF)
Acknowledgments
We thank Silke Schu ¨le (PEI) for helpful discussions, Rumana Huq and
Lauren O’Rourke (Microscopy Shared Research Facility, MSSM, NY,
NY) for expert assistance with live cell fluorescence microscopy imaging.
Author Contributions
Conceived and designed the experiments: AB VS AFS LCFM RK EF.
Performed the experiments: AB AFRS JZ MH KW NE SP AR AJ IR VS.
Analyzed the data: AB AFRS JZ MH AR VS RK EF AFS. Contributed
reagents/materials/analysis tools: FR AR LCFM AFS. Wrote the paper:
AB AFRS MH VS AFS LCFM RK EF.
References
1. Sonza S, Maerz A, Deacon N, Meanger J, Mills J, et al. (1996) Human
immunodeficiency virus type 1 replication is blocked prior to reverse
transcription and integration in freshly isolated peripheral blood monocytes.
J Virol 70: 3863–3869.
2. Neil S, Martin F, Ikeda Y, Collins M (2001) Postentry restriction to human
immunodeficiency virus-based vector transduction in human monocytes. J Virol
75: 5448–5456. 10.1128/JVI.75.12.5448-5456.2001 [doi].
3. Kaushik R, Zhu X, Stranska R, Wu Y, Stevenson M (2009) A cellular restriction
dictates the permissivity of nondividing monocytes/macrophages to lentivirus
and gammaretrovirus infection. Cell Host Microbe 6: 68–80.
4. Negre D, Mangeot PE, Duisit G, Blanchard S, Vidalain PO, et al. (2000)
Characterization of novel safe lentiviral vectors derived from simian immuno-
deficiency virus (SIVmac251) that efficiently transduce mature human dendritic
cells. Gene Ther 7: 1613–1623. 10.1038/sj.gt.3301292 [doi].
5. Fujita M, Otsuka M, Nomaguchi M, Adachi A (2010) Multifaceted activity of
HIV Vpr/Vpx proteins: the current view of their virological functions. Rev Med
Virol 20: 68–76.
6. Goujon C, Arfi V, Pertel T, Luban J, Lienard J, et al. (2008) Characterization of
simian immunodeficiency virus SIVSM/human immunodeficiency virus type 2
Vpx function in human myeloid cells. J Virol 82: 12335–12345.
7. Yu XF, Yu QC, Essex M, Lee TH (1991) The vpx gene of simian
immunodeficiency virus facilitates efficient viral replication in fresh lymphocytes
and macrophage. J Virol 65: 5088–5091.
8. Hirsch VM, Sharkey ME, Brown CR, Brichacek B, Goldstein S, et al. (1998)
Vpx is required for dissemination and pathogenesis of SIV(SM) PBj: evidence of
macrophage-dependent viral amplification. Nat Med 4: 1401–1408.
9. Berger A, Munk C, Schweizer M, Cichutek K, Schule S, et al. (2010) Interaction
of Vpx and apolipoprotein B mRNA-editing catalytic polypeptide 3 family
member A (APOBEC3A) correlates with efficient lentivirus infection of
monocytes. J Biol Chem 285: 12248–12254.
10. Schule S, Kloke BP, Kaiser JK, Heidmeier S, Panitz S, et al. (2009) Restriction
of HIV-1 replication in monocytes is abolished by Vpx of SIVsmmPBj. PLoS
One 4: e7098.
11. Goujon C, Jarrosson-Wuilleme L, Bernaud J, Rigal D, Darlix JL, et al. (2006)
With a little help from a friend: increasing HIV transduction of monocyte-
derived dendritic cells with virion-like particles of SIV(MAC). Gene Ther 13:
991–994.
12. Gramberg T, Sunseri N, Landau NR (2010) Evidence for an activation domain
at the amino terminus of simian immunodeficiency virus Vpx. J Virol 84:
1387–1396.
13. Accola MA, Bukovsky AA, Jones MS, Gottlinger HG (1999) A conserved
dileucine-containing motif in p6(gag) governs the particle association of Vpx and
Vpr of simian immunodeficiency viruses SIV(mac) and SIV(agm). J Virol 73:
9992–9999.
14. Strebel K, Luban J, Jeang KT (2009) Human cellular restriction factors that
target HIV-1 replication. BMC Med 7: 48. 1741-7015-7-48 [pii];10.1186/1741-
7015-7-48 [doi].
15. Wolf D, Goff SP (2008) Host restriction factors blocking retroviral replication.
Annu Rev Genet 42: 143–163. 10.1146/annurev.genet.42.110807.091704 [doi].
16. Bergamaschi A, Ayinde D, David A, Le Rouzic E, Morel M, et al. (2009) The
human immunodeficiency virus type 2 Vpx protein usurps the CUL4A-DDB1
DCAF1 ubiquitin ligase to overcome a postentry block in macrophage infection.
J Virol 83: 4854–4860.
17. Sharova N, Wu Y, Zhu X, Stranska R, Kaushik R, et al. (2008) Primate
lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction.
PLoS Pathog 4: e1000057.
Figure 5. Cytokine secretion of PBMC lacking SAMHD1 indicates an early inflammatory response during HIV-1 replication. The
culture supernatants of HIV-1 R7/3 YU2 EGFP infected and non-infected PBMC of the SAMHD1-deficient Donor 2 and the healthy Donor 4 as
described in Figure 3D were subjected to Multiplex ELISA and analyzed for time-dependent secretion of the indicated chemokines and cytokines. The
results are presented as cytokine concentrations for SAMHD1-deficient Donor 2 in the absence (purple lines) or presence (green lines) of HIV-1
infection and as fold induction upon HIV-1 infection over the mock infected controls for SAMHD1-deficient Donor 2 (yellow lines) and healthy Donor
4 (blue lines).
doi:10.1371/journal.ppat.1002425.g005
SAMHD1 Protects Monocytes from HIV-1 Infection
PLoS Pathogens | www.plospathogens.org 11 December 2011 | Volume 7 | Issue 12 | e100242518. Goujon C, Riviere L, Jarrosson-Wuilleme L, Bernaud J, Rigal D, et al. (2007)
SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-
dependent restriction pathway present in human dendritic cells. Retrovirology 4:
2.
19. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, et al.
(2011) Vpx relieves inhibition of HIV-1 infection of macrophages mediated by
the SAMHD1 protein. Nature 474: 658–661. nature10195 [pii];10.1038/
nature10195 [doi].
20. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, et al. (2011)
SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor
counteracted by Vpx. Nature 474: 654–657. nature10117 [pii];10.1038/
nature10117 [doi].
21. Crow YJ, Livingston JH (2008) Aicardi-Goutieres syndrome: an important
Mendelian mimic of congenital infection. Dev Med Child Neurol 50: 410–416.
DMCN02062 [pii];10.1111/j.1469-8749.2008.02062.x [doi].
22. Lee-Kirsch MA (2010) Nucleic acid metabolism and systemic autoimmunity
revisited. Arthritis Rheum 62: 1208–1212. 10.1002/art.27372 [doi].
23. Dussaix E, Lebon P, Ponsot G, Huault G, Tardieu M (1985) Intrathecal
synthesis of different alpha-interferons in patients with various neurological
diseases. Acta Neurol Scand 71: 504–509.
24. Yan N, Regalado-Magdos AD, Stiggelbout B, Lee-Kirsch MA, Lieberman J
(2010) The cytosolic exonuclease TREX1 inhibits the innate immune response
to human immunodeficiency virus type 1. Nat Immunol 11: 1005–1013.
ni.1941 [pii];10.1038/ni.1941 [doi].
25. Rice GI, Bond J, Asipu A, Brunette RL, Manfield IW, et al. (2009) Mutations
involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the
innate immune response. Nat Genet 41: 829–832. ng.373 [pii];10.1038/ng.373
[doi].
26. du MM, Nurnberg P, Crow YJ, Rutsch F (2011) Cerebral vasculopathy is a
common feature in Aicardi-Goutieres syndrome associated with SAMHD1
mutations. Proc Natl Acad Sci U S A 108: e232. 1104699108 [pii];10.1073/
pnas.1104699108 [doi].
27. Ramesh V, Bernardi B, Stafa A, Garone C, Franzoni E, et al. (2010)
Intracerebral large artery disease in Aicardi-Goutieres syndrome implicates
SAMHD1 in vascular homeostasis. Dev Med Child Neurol 52: 725–732.
DMCN3727 [pii];10.1111/j.1469-8749.2010.03727.x [doi].
28. Thiele H, du MM, Barczyk K, George C, Schwindt W, et al. (2010) Cerebral
arterial stenoses and stroke: novel features of Aicardi-Goutieres syndrome caused
by the Arg164X mutation in SAMHD1 are associated with altered cytokine
expression. Hum Mutat 31: E1836–E1850. 10.1002/humu.21357 [doi].
29. Xin B, Jones S, Puffenberger EG, Hinze C, Bright A, et al. (2011) Homozygous
mutation in SAMHD1 gene causes cerebral vasculopathy and early onset stroke.
Proc Natl Acad Sci U S A 108: 5372–5377. 1014265108 [pii];10.1073/
pnas.1014265108 [doi].
30. Srivastava S, Swanson SK, Manel N, Florens L, Washburn MP, et al. (2008)
Lentiviral Vpx accessory factor targets VprBP/DCAF1 substrate adaptor for
cullin 4 E3 ubiquitin ligase to enable macrophage infection. PLoS Pathog 4:
e1000059.
31. Wiskerchen M, Muesing MA (1995) Human immunodeficiency virus type 1
integrase: effects of mutations on viral ability to integrate, direct viral gene
expression from unintegrated viral DNA templates, and sustain viral
propagation in primary cells. J Virol 69: 376–386.
32. Feinberg MB, Jarrett RF, Aldovini A, Gallo RC, Wong-Staal F (1986) HTLV-
III expression and production involve complex regulation at the levels of splicing
and translation of viral RNA. Cell 46: 807–817. 0092-8674(86)90062-0 [pii].
33. Munoz C, Misset B, Fitting C, Bleriot JP, Carlet J, et al. (1991) Dissociation
between plasma and monocyte-associated cytokines during sepsis. Eur J
Immunol 21: 2177–2184. 10.1002/eji.1830210928 [doi].
34. de Bont ES, Kimpen JL, Tamminga RY, Niemarkt AE, de Leij LH, et al. (2000)
Intrinsic capacity of monocytes to produce cytokines ex vivo in patients with
acute lymphoblastic leukaemia. Cytokine 12: 1723–1726. 10.1006/
cyto.2000.0776 [doi];S1043-4666(00)90776-2 [pii].
35. Kaiser SE, Riley BE, Shaler TA, Trevino RS, Becker CH, et al. (2011) Protein
standard absolute quantification (PSAQ) method for the measurement of cellular
ubiquitin pools. Nat Methods 8: 691–696. nmeth.1649 [pii];10.1038/
nmeth.1649 [doi].
36. Qiao F, Bowie JU (2005) The many faces of SAM. Sci STKE 2005:re7.
stke.2862005re7 [pii];10.1126/stke.2862005re7 [doi].
37. Oberstrass FC, Lee A, Stefl R, Janis M, Chanfreau G, et al. (2006) Shape-
specific recognition in the structure of the Vts1p SAM domain with RNA. Nat
Struct Mol Biol 13: 160–167. nsmb1038 [pii];10.1038/nsmb1038 [doi].
38. Zimmerman MD, Proudfoot M, Yakunin A, Minor W (2008) Structural insight
into the mechanism of substrate specificity and catalytic activity of an HD-
domain phosphohydrolase: the 59-deoxyribonucleotidase YfbR from Escherichia
coli. J Mol Biol 378: 215–226. S0022-2836(08)00233-7 [pii];10.1016/
j.jmb.2008.02.036 [doi].
39. Aravind L, Koonin EV (1998) The HD domain defines a new superfamily of
metal-dependent phosphohydrolases. Trends Biochem Sci 23: 469–472. S0968-
0004(98)01293-6 [pii].
40. Oussenko IA, Sanchez R, Bechhofer DH (2002) Bacillus subtilis YhaM, a
member of a new family of 39-to-59 exonucleases in gram-positive bacteria.
J Bacteriol 184: 6250–6259.
41. Neil S, Bieniasz P (2009) Human immunodeficiency virus, restriction factors,
and interferon. J Interferon Cytokine Res 29: 569–580. 10.1089/jir.2009.0077
[doi].
42. Uchil PD, Quinlan BD, Chan WT, Luna JM, Mothes W (2008) TRIM E3
ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathog
4: e16. 07-PLPA-RA-0403 [pii];10.1371/journal.ppat.0040016 [doi].
43. Berger G, Durand S, Fargier G, Nguyen XN, Cordeil S, et al. (2011)
APOBEC3A Is a Specific Inhibitor of the Early Phases of HIV-1 Infection in
Myeloid Cells. PLoS Pathog 7: e1002221.
44. Arhel N (2010) Revisiting HIV-1 uncoating. Retrovirology 7: 96. 1742-4690-7-
96 [pii];10.1186/1742-4690-7-96 [doi].
45. Connor RI, Chen BK, Choe S, Landau NR (1995) Vpr is required for efficient
replication of human immunodeficiency virus type-1 in mononuclear phago-
cytes. Virology 206: 935–944. S0042-6822(85)71016-1 [pii];10.1006/
viro.1995.1016 [doi].
46. Rodriguez-Madoz JR, Belicha-Villanueva A, Bernal-Rubio D, Ashour J,
Ayllon J, et al. (2010) Inhibition of the type I interferon response in human
dendritic cells by dengue virus infection requires a catalytically active NS2B3
complex. J Virol 84: 9760–9774. JVI.01051-10 [pii];10.1128/JVI.01051-10
[doi].
SAMHD1 Protects Monocytes from HIV-1 Infection
PLoS Pathogens | www.plospathogens.org 12 December 2011 | Volume 7 | Issue 12 | e1002425